Ro 41-1049 

Ro 41-1049 is a highly selective, reversible MAO-A inhibitor. Ro 41-1049 effectively blocks the Quinpirole (HY-B1752)-induced increase in dopamine D2-like receptor density in the nucleus accumbens and alters the pattern of behavioral sensitization, shifting animals' responses from enhanced motor activity to immobile self-directed gaping behavior. Tritium-labeled Ro 41-1049 serves as a high-affinity radioligand, enabling accurate mapping of the distribution and abundance of MAO-A in the central nervous system, peripheral organs, and human brain via quantitative enzyme autoradiography. Ro 41-1049 can be used for basic research on depression and other related diseases^[1][2][3].

Ro 41-1049 (10 μM; 4 hrs) inhibits a portion of in vitro [³H]quinpirole binding to dopamine D₂-like receptors in nucleus accumbens and striatum tissue homogenates, though this inhibitory effect is not modulated by prior in vivo quinpirole or Ro 41-1049 treatments^[1].
Tritiated Ro 41-1049 (1-150 nM; 60 min) binds to MAO-A in rat cerebral cortex sections with high affinity (K_d = 10.7 nM) and a maximum binding capacity of 7.38 pmol/mg protein, with consistent high-affinity binding across rat brain regions^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pre-treatment with Ro 41-1049 (1 mg/kg; s.c.; 90 minutes prior to each Quinpirole injection; twice weekly for 8 pairs of injections) prevents Quinpirole-induced increases in dopamine D₂-like receptor density in the nucleus accumbens and shifts quinpirole-induced behavioral sensitization from locomotion to 7-fold higher self-directed mouthing activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

265.31

C₁₂H₁₂FN₃OS

127500-84-9

O=C(NCCN)C=1N=CSC1C=2C=CC=C(F)C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Culver KE, et al.. Altered dopamine D2-like receptor binding in rats with behavioral sensitization to quinpirole: effects of pre-treatment with Ro 41-1049. European journal of pharmacology. 2008 Sep 11;592(1-3):67-72.  [Content Brief]

  [2]. Saura J, et al. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain[J]. Journal of Neuroscience, 1992, 12(5): 1977-1999.

  [3]. Da Prada M, et al. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors[C]//Neurotransmitter Actions and Interactions: Proceedings of a Satellite Symposium of the 12th International Society for Neurochemistry Meeting, Algarve, Portugal, April 29–30, 1989. Vienna: Springer Vienna, 1990: 279-292.